Gabapentin Abuse, and Delirium Tremens Upon Gabapentin Withdrawal

Sir: Gabapentin is one of a new generation of antiepileptic drugs widely used in recent years for a variety of indications, including epilepsy, neuropathic pain, migraine, and bipolar disorder. Although gabapentin is structurally analogous to γ-aminobutyric acid (GABA), it does not appear to affect GABA uptake or the GABA \( \alpha \) or GABA \( \beta \) receptors. The basis of its anticonvulsant efficacy is unclear, but it may include inhibition of certain voltage-activated calcium channels. \(^1\) Gabapentin increases brain GABA concentration and turnover. \(^2\) Given this effect, it is perhaps not surprising that several studies have shown that gabapentin decreases alcohol withdrawal symptoms and may decrease cravings for alcohol in alcohol-dependent individuals. \(^3,4\)

While gabapentin has low abuse potential, abuse has been described in cocaine-dependent individuals. One report describes the abuse of gabapentin by snorting in 5 cocaine-dependent prison inmates. \(^5\) Another case report describes a patient who reported reduced cocaine craving through the use of 600 to 1500 mg/day of gabapentin, prescribed for another individual. \(^6\)

A small number of reports have described withdrawal symptoms after discontinuation of gabapentin. Norton \(^7\) described 3 cases of withdrawal in patients taking 4800, 3600, and 2400 mg/day: the first 2 developed elevated vital signs, confusion, agitation, and diaphoresis over a 2- to 3-day period, and the last developed irritability, headache, and diaphoresis over a 2-day period. A case similar to this last is also described by Draikin and Calhoun. \(^8\) Another patient taking 8000 mg/day developed status epilepticus 3 days after discontinuation of drug. \(^9\) Yet another patient developed catatonia after gabapentin discontinuation. \(^10\) This is notable because catatonia has been described after withdrawal from benzodiazepines, which also increase GABA transmission. Here we describe 2 patients who used larger doses of gabapentin than prescribed and who then developed a withdrawal syndrome similar to delirium tremens upon discontinuation of the drug.

Case 1. Mr. A, a 33-year-old man, had a history of hepatitis C. He had a history of alcohol and other drug dependence, including a history of delirium tremens with alcohol withdrawal, but he had been using only cannabis, according to multiple reliable sources, for at least 6 months prior to the admission reported here. However, for at least that time he had been taking 3600 mg/day of gabapentin, twice his prescribed dose, because he felt the medication reduced his cravings for alcohol and made him feel calmer. Office staff routinely authorized early refills. He was also prescribed paroxetine and quetiapine. In 2005, he ran out of gabapentin and abruptly stopped the medication after office staff were instructed not to permit early refills. On the third day off gabapentin, he was found by a roommate to be confused and diaphoretic and was brought to the hospital. He was disoriented, agitated, tachycardic, hyperreflexic, and tremulous, and he was admitted to the hospital. He was treated with lorazepam (to a total of 6 mg) and haloperidol (to a total of 10 mg) on hospital day 2 without benefit. Gabapentin was resumed on hospital day 3 at 600 mg every 8 hours, and his symptoms resolved fully over the next 2 days. No oculomotor palsy, pendular nystagmus, or ataxia was seen. No other etiology for this mental status change was found. On admission, urine toxicology screen was positive only for cannabis, and blood alcohol screen was negative. Mean corpuscular volume was within normal limits.

Case 2. Mr. B, a 63-year-old man, had a medical history significant for severe chronic back pain and multiple back surgeries. At the time of presentation, he was being prescribed and was taking oxycodone and gabapentin. He had a history of significant alcohol use in the past but had used none in over a decade. In 2005, he presented to the emergency department after several days of fatigue, increasing sedation, and confusion. He was found to have taken an average estimated daily dose of 4900 mg of gabapentin for the last 11 days, although it was prescribed at 1800 mg/day. Investigation determined that he had been using similarly high doses of gabapentin for many months. He was treated with a total lorazepam dose of 4 mg on each of the first and second days in hospital for periods of agitation. Gabapentin was stopped. On the third day in hospital, he was noted to be confused and hallucinating. He rapidly became tachycardic to 120 b.p.m., febrile to 100.5°F, diaphoretic, tremulous, and agitated. He was treated with 26 mg of lorazepam on hospital day 4 and with 22 mg of lorazepam on hospital day 5, with limited improvement. Gabapentin was resumed at 300 mg every 6 hours on hospital day 6. He quickly became more lucid, and his vital signs stabilized. As in the first case, the examination findings were not consistent with a Wernicke syndrome, and work-up did not disclose any other etiology for his change of mental status. The patient made a full recovery.

Several classes of drugs that modulate GABAergic neurotransmission, including ethanol, benzodiazepines, and barbiturates, have abuse potential. Gabapentin abuse has previously been described in individuals with a history of cocaine dependence. Our observations suggest that gabapentin abuse can also occur in individuals with a history of heavy alcohol use. To our knowledge, gabapentin abuse has only been described in individuals with a history of exposure to addictive substances.

Cessation of ethanol, benzodiazepines, or barbiturates can produce a withdrawal delirium. Both cases described here demonstrated all of the cardinal features of delirium tremens, or alcohol withdrawal delirium, as defined by the DSM-IV-TR. \(^11\) Both patients received lorazepam in the hospital, with possible benefit in 1 case. Whether benzodiazepines are useful in the treatment of gabapentin withdrawal is unclear from these 2 narratives. Both patients, as well as the 2 other reported cases of confusion during gabapentin withdrawal, were using doses of 3600 mg/day or higher. It may be that severe withdrawal reactions will be observed only with relatively high daily doses of this drug. The combination of abuse potential and a physiologically significant withdrawal syndrome emphasizes that gabapentin may share some of the undesirable characteristics of other pharmacologic agents that modulate GABAergic neurotransmission.

The authors report no financial affiliation or other relationships that can be considered a conflict of interest relevant to the subject of this letter.

REFERENCES

Chronic Leukocytosis Associated With Clozapine: A Case Series

Sir: The potential for clozapine, a dibenzodiazepine derivative, to cause leukopenia/agranulocytosis is well-known; however, leukocytosis associated with clozapine has been reported infrequently, particularly in the U.S. literature. Persistent clozapine-associated leukocytosis without fever or other complications is rarely reported. Leukocytosis, defined as a white blood cell (WBC) count greater than 11,000/mm³ (11 × 10⁹/L), is frequently found in the course of routine laboratory testing. An elevated WBC count reflects the typical response of bone marrow to infectious or inflammatory processes.

Leukocytosis can occur as a result of physical and emotional stress, such as overexertion, seizures, anxiety, anesthgesia, and epinephrine administration. However, this process is a transient one that is not related to marrow production or the release of immature blood cells. Other causes of leukocytosis that may be persistent include medications, splenectomy, hemolytic anemia, and malignancy. Medications that have been reported to cause leukocytosis include corticosteroids, lithium, and β-agonists. High smoking rates are associated with increases in total and differential WBC counts.

The incidence of hematologic adverse effects in clinical trials of clozapine was as follows: leukopenia/decreased WBC/neutropenia = 3%, agranulocytosis = 1%, and eosinophilia = 1%. Less frequent (< 1%) hematologic adverse effects in premarketing trials included anemia and leukocytosis. Postmarketing clinical experience revealed reports of elevated hemoglobin/hematocrit, increased erythrocytic sedimentation rate, thrombocytosis, and thrombocytopenia.

We report cases of chronic leukocytosis in afebrile patients in this case series from the clinical experience of the first author (S.M.) in nursing homes.

Method

All cases of chronic leukocytosis associated with clozapine use from the clinical practice of the first author (S.M.) during a 5-year period, for which other etiologic factors have been excluded, were analyzed retrospectively. All cases of transient and intermittent leukocytosis were excluded. The study was approved by the Institutional Review Board of St. John’s Episcopal Hospital, Far Rockaway, N.Y. Demographic factors like age, sex, concurrent medication—psychotropics and nonpsychotropics—concurrent medical diagnosis, dose of clozapine and duration of treatment, psychiatric diagnosis, and at least 3 WBC counts (total and differential) during a 2- to 5-year period were reviewed. Case histories are summarized in the Results section and Table 1 and representative data are provided for all patients in Figure 1.

Results

All patients in this case series are residents of nursing homes where vital signs are monitored on a regular basis by nursing staff. Patients are seen by the primary care doctor at least monthly and by the psychiatrist every 1 to 3 months. All patients have been under care of the first author (S.M.); some have been evaluated and worked up by the hematologist and coauthor (L.C.). All patients in this case series are smokers who are allowed 6 cigarettes/day. Since patients are in a structured setting, smoking is controlled. None of the patients had any active infections manifested by fever or corresponding changes in blood counts or any other common etiologic factors for leukocytosis. No patients in this case series had any bone marrow studies done, since the leukocytosis was chronic and appeared to be related to the clozapine use. No patients in this series had any adverse consequences related to the leukocytosis.

Case 1. Mr. A is a 42-year-old black man who has been living in the nursing home for the past 7 to 8 years. He has a history of long-term psychiatric hospitalization in a state psychiatric center. Mr. A’s diagnoses at admission to the nursing home included chronic paranoid schizophrenia, mental retardation, and hyperlipidemia. He had a history of polysubstance abuse as a teenager. He was placed in the nursing home from the state hospital, where he had been taking a combination of risperidone 2 mg and clozapine 600 mg PO daily. At admission to the nursing home, risperidone was discontinued, and the clozapine dose was tapered gradually to 450 mg PO h.s. and has been maintained at that level for the past 5 years. Clozapine was originally started in 1996 at the state hospital. Mr. A is a smoker, and since being in the nursing home, is allowed 6 cigarettes per day. His WBC count was elevated prior to admission and has continued to be elevated since he has been in the nursing home. WBC counts were monitored every 2 weeks. Absolute neutrophil count has been monitored only since 2005, when the new monitoring guidelines for clozapine were implemented. WBC counts have been consistently elevated, and some representative values are shown in Table 1 and Figure 1. Mr. A continues to be monitored in the nursing home.

Case 2. Mr. B is a 43-year-old white man admitted to the nursing home in 2000 from a state psychiatric center. He was taking olanzapine 10 mg PO h.s. and clozapine 300 mg PO b.i.d. on admission. Olanzapine was discontinued, and Mr. B was maintained on the clozapine therapy. However, he decompensated and was hospitalized several times, after which he was placed on combination therapy of clozapine with perphenazine. Mr. B’s diagnosis included chronic paranoid schizophrenia, coronary artery disease, hypertension, and peptic ulcer disease. He had no history of drug or alcohol abuse.

He had sporadic mild leukocytosis from 2000 to 2002. At the end of 2002, Mr. B had a medical hospitalization at which time clozapine and perphenazine treatment were discontinued and olanzapine therapy started. He decompensated very quickly and...
had to be rehospitalized psychiatrically in March 2003. His WBC counts were within normal limits when he was taken off the clozapine therapy. He was restarted on clozapine therapy in March 2003, and dosage was increased up to 550 mg/day. Mr. B was also started on sodium valproate therapy up to 500 mg PO b.i.d. WBC counts were monitored weekly for 6 months, then twice a month for the next 6 months, and on a monthly basis thereafter. During his treatment with clozapine, for the second time, Mr. B has had consistently elevated WBC counts (higher than during his earlier treatment phase). Mr. B is a smoker who is allowed 6 cigarettes per day. He showed no evidence of infection or other common causes of leukocytosis, nor did he show any adverse effects of the leukocytosis. He continues to be monitored in the nursing home.

**Case 3.** Mr. C is a 47-year-old white man admitted to the nursing home in June 2004. He has a long history of multiple psychiatric hospitalizations in state and community hospital psychiatric units. He was started on clozapine therapy prior to 1998—exact dates are unavailable. Mr. C has a history of schizoaffective disorder and hypertension. There is no history of drug or alcohol abuse.

He has been taking clozapine, quetiapine, clonazepam, and escitalopram from admission. Mr. C’s WBC counts have been consistently elevated since admission. He is a smoker who is allowed 6 cigarettes/day. He has not shown any evidence of infection or other common causes of leukocytosis, nor did he show any adverse effects of leukocytosis. He continues to be monitored in the nursing home.

**Case 4.** Mr. D is a 52-year-old white man admitted to the nursing home in 2002. He has a history of multiple psychiatric hospitalizations and had lived in an adult home prior to his nursing home placement. He has been taking clozapine since admission. Mr. D has a history of chronic paranoid schizophrenia, hypertension, and peptic ulcer disease. He has had mild leukocytosis since admission. He has no history of drug or alcohol abuse. Mr. D is a smoker who smokes up to 6 cigarettes/day. He showed no evidence of infection or other common causes of leukocytosis, nor did he show any adverse effects of leukocytosis. Mr. D continues to be monitored in the nursing home.

**Case 5.** Mr. E is a 48-year-old white man admitted to the nursing home in November 2002. He has a history of multiple psychiatric hospitalizations for chronic paranoid schizophrenia, seizure disorder, hypertension, and hyponatremia. He has no history of drug or alcohol abuse. Mr. E is a smoker who is allowed 6 cigarettes/day. He has been taking clozapine from admission, and his WBC counts have been consistently elevated since admission. Mr. E showed no evidence of infection or other common causes of leukocytosis, nor did he show any adverse effects of leukocytosis. Mr. E continues to be monitored in the nursing home.

**Case 6.** Mr. F is a 51-year-old black man admitted to the nursing home in February 2001. He has a history of multiple psychiatric hospitalizations for chronic undifferentiated schizophrenia. He also has a history of hypertension, cellulitis, congestive heart failure, and diabetes mellitus. He has no history of drug or alcohol abuse. His cellulitis was treated prior to placement in the nursing home. Mr. F has been taking clozapine and olanzapine from admission, and his WBC counts have been consistently elevated. He is a smoker who is allowed 6 cigarettes/day. Mr. F did not show any evidence of infection or other common causes of leukocytosis, nor did he show any adverse effects of leukocytosis. He was discharged from the nursing home in early 2004 and lost to follow-up.

**Case 7.** Mr. G is a 52-year-old black man admitted to the nursing home in June 2002. He has a history of multiple psychiatric hospitalizations in community hospital psychiatric units and state psychiatric facilities. He has a history of chronic paranoid schizophrenia and polysubstance abuse. His medical diagnoses included diabetes mellitus, hypertension, benign prostatic hypertrophy, and gastroesophageal reflux disease.

At admission to the nursing home, Mr. G was taking sodium valproate, benztrapine mesylate, haloperidol, and haloperidol decanoate. In September 2002, haloperidol was discontinued due to extrapyramidal symptoms, and he was started on quetiapine therapy up to 700 mg/day. His WBC counts during admission and yearly follow-up reports were within normal limits. Mr. G is a smoker and has been smoking about 1 to 3 cigarettes/day since placement. He was readmitted to the psychiatric unit due to worsening psychotic symptoms in May 2003. Quetiapine was discontinued, and clozapine was started; dosage was titrated to 250 mg/day. Mr. G was returned to the nursing home in early June 2003. All WBC counts up to September 2003 had been within normal limits. Leukocytosis was noted from early September 2003, when WBC counts were being monitored on a weekly basis. Clozapine was increased to 450 mg/day. Mr. G showed consistent mild leukocytosis. He showed no evidence of infection or other causes of leukocytosis, nor did he show any adverse effects of leukocytosis. Mr. G started refusing the blood work around April 2006, and clozapine was discontinued. Mr. G was started on meldonide hydrochloride therapy. His WBC counts have been within normal limits since the discontinuation of clozapine. He continues to be monitored. We have been able to follow Mr. G before, during, and after treatment with clozapine. The leukocytosis was noted only during clozapine treatment.

There were 7 patients identified with chronic leukocytosis in this case series. All patients (100%) were male—4 (57%) white and 3 (43%) black. The mean age was 47.8 years (range, 42–52 years). Six patients (86%) had schizophrenia, and 1 (14%) had schizoaffective disorder. Six patients (86%) had hypertension, and 5 were taking antihypertensive medications. The mean daily dose of clozapine was 457 mg (range, 50–600 mg). The mean total WBC count was 13.6 × 10³/µL (range, 11.3–19.1 × 10³/µL). There were no constant changes in the differential count. Chronic leukocytosis has been tracked for a period of 2 to 5 years in these patients (Table 1). There were no clinical consequences of the leukocytosis noted in these patients. Other
<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age</th>
<th>Sex</th>
<th>Race</th>
<th>Psychiatric Diagnosis</th>
<th>Medical Diagnosis</th>
<th>Concurrent Medication</th>
<th>Clozapine dose/day or Other Psychotropic Medication</th>
<th>WBC Total Count</th>
<th>Date</th>
<th>Differential Count Abnormalities</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>42</td>
<td>Male</td>
<td>Black</td>
<td>Chronic paranoid schizophrenia</td>
<td>Mental retardation</td>
<td>Hyperlipidemia</td>
<td>Lovastatin</td>
<td>Clozapine 450 mg</td>
<td>14.1 x 10^9/µL</td>
<td>11/2/99</td>
<td>None</td>
</tr>
<tr>
<td>2</td>
<td>43</td>
<td>Male</td>
<td>White</td>
<td>Chronic paranoid schizophrenia</td>
<td>Heart disease</td>
<td>Hypertension</td>
<td>Atenolol, Ranitidine, Acetylsalicylic acid</td>
<td>Clozapine 550 mg</td>
<td>13.7 x 10^9/µL</td>
<td>4/04/03</td>
<td>AN = 13 x 10^9/µL</td>
</tr>
<tr>
<td>3</td>
<td>47</td>
<td>Male</td>
<td>White</td>
<td>Schizoaffection disorder</td>
<td>Heart disease</td>
<td>Hypertension</td>
<td>Nisoldipine, Zoledropin, Tridephsine, Hydrochloride</td>
<td>Clozapine 600 mg</td>
<td>16.6 x 10^9/µL</td>
<td>6/03/04</td>
<td>AN = 15.0 x 10^9/µL</td>
</tr>
<tr>
<td>4</td>
<td>52</td>
<td>Male</td>
<td>White</td>
<td>Chronic paranoid schizophrenia</td>
<td>Heart disease</td>
<td>Hypertension</td>
<td>Atenolol, Risedronate sodium</td>
<td>Clozapine 600 mg</td>
<td>11.4 x 10^9/µL</td>
<td>11/18/03</td>
<td>E = 0%</td>
</tr>
<tr>
<td>5</td>
<td>48</td>
<td>Male</td>
<td>White</td>
<td>Chronic paranoid schizophrenia</td>
<td>Heart disease</td>
<td>Seizure disorder</td>
<td>Sodium valproate</td>
<td>Clozapine 600 mg</td>
<td>12.4 x 10^9/µL</td>
<td>11/18/03</td>
<td>N = 78%</td>
</tr>
<tr>
<td>6</td>
<td>51</td>
<td>Male</td>
<td>Black</td>
<td>Chronic undifferentiated schizophrenia</td>
<td>Heart disease</td>
<td>Hypertension</td>
<td>Furosemide, Glipizide, Verapamil</td>
<td>Clozapine 50 mg</td>
<td>11.8 x 10^9/µL</td>
<td>9/19/02</td>
<td>None</td>
</tr>
<tr>
<td>7</td>
<td>52</td>
<td>Male</td>
<td>Black</td>
<td>Chronic paranoid schizophrenia</td>
<td>Diabetes mellitus</td>
<td>Hyperlipidemia</td>
<td>Nisoldipine, Lovastatin, Metformin, Glipizide, Terazosin, Omeprazole, Ibuprofen</td>
<td>Clozapine 450 mg</td>
<td>12.2 x 10^9/µL</td>
<td>9/03</td>
<td>AE = 0.1 x 10^9/µL</td>
</tr>
</tbody>
</table>

*Normal values: AE = 0 to 0.7 x 10^9/µL, AM = 0.1 to 1.0 x 10^9/µL, AN = 1.6 to 7.8 x 10^9/µL, B = 0% to 1.0%, E = 1.0% to 4.0%, L = 20.0% to 40.0%, M = 2.0% to 10.0%, N = 40.0% to 70.0%.
*Clozapine started 03/03.
*Clozapine started before 1998.
*Clozapine started before 03/03.
*Clozapine started before 03/03.
*Clozapine started before 03/03.
*Clozapine started before 03/03.
*Clozapine started 03/03.

Abbreviations: AE = absolute eosinophil count, AL = absolute lymphocyte count, AM = absolute monocyte count, AN = absolute neutrophil count, B = basophil count, E = eosinophil count, L = lymphocyte count, M = monocyte count, N = neutrophil count, WBC = white blood cell.
Abstract

Chronic leukocytosis, even though infrequent, appears to be a potential side effect of clozapine, and it is generally benign. Long-term analysis of the clozapine monitoring system data will be of help in further investigating this issue.

Discussion

A number of factors routinely cause leukocytosis: relatively benign conditions like infection; inflammatory response to tissue necrosis, infarction, burns, and arthritis; stress-related situations like overexertion, seizures, anxiety, and anesthesia; drugs like corticosteroids, lithium, and β agonists; and trauma (e.g., splenectomy). When WBC counts are extremely elevated or there are concurrent abnormalities in red blood cells or platelet counts, primary bone marrow disorders should be suspected. As Abramson et al. characterize it, “The circulating pool of neutrophils is divided into 2 classes. One pool of cells is circulating freely and the second pool deposited along the margins of blood vessel walls. In response to infection, inflammation, drugs or metabolic toxins, the deposited cells 'demarginate' and enter the vessel walls. In 2 patients (cases 2 and 7) in whom clozapine was discontinued, WBC counts, primary bone marrow disorders should be suspected."

Etiology

The etiology of leukocytosis associated with clozapine use is unknown. There are sporadic reports of leukocytosis associated with clozapine use. In the report by Seifritz et al., the leukocytosis was thought to be secondary to rehabilitation stress. A case report of persistent leukocytosis associated with clozapine by Trinidad et al. is complicated by the concurrent use of lithium. In the case reported by Popli and Pies, the patient had had a splenectomy, which could have contributed to the leukocytosis.

A recent case of persistent leukocytosis associated with clozapine, and followed up for over 10 months, has been reported. Even though a thorough medical workup did not identify any causative factors in this case, the patient is reported to be a chronic smoker, using 20 to 30 cigarettes daily. High smoking rate is associated with an increase in WBC count. Chronic smoking causes phenotypic changes in circulating polymorphonuclear leukocytes that are characteristic of chronic stimulation of the bone marrow. Animal studies have shown that chronic smoking shortens the transit time of polymorphonuclear leukocytes through the bone marrow.

Leukopenia and agranulocytosis associated with clozapine use have been investigated extensively. Neutropenia associated with clozapine is thought to be secondary to a cytotoxic effect on the committed progenitor cell compartment but not on primitive hematopoietic cells. The risk for agranulocytosis appears elevated in the elderly, women, and patients of Ashkenazi Jewish descent with HLA-B38 phenotype. The etiology and risk factors for leukocytosis associated with clozapine are unknown. In our small case series of 7 patients, there is no significant difference in racial distribution. Interestingly, all patients were males between the ages of 42 and 52 years. Male sex may be a risk factor for leukocytosis. All patients reported in the literature with chronic or persistent leukocytosis associated with clozapine use are male.

Eighty-six percent of patients had schizophrenia. None of the patients had any medical illnesses with known propensity to cause leukocytosis. None of the concurrent medications patients were taking are known to cause leukocytosis except omeprazole, in rare instances. However, the patient who was taking omeprazole showed no evidence of leukocytosis prior to clozapine treatment despite taking omeprazole.

Most of the concurrent medications listed in Table 1 can cause leukopenia/agranulocytosis in rare instances. Lovastatin can cause eosinophilia in rare instances. The patient who was taking lovastatin did not have eosinophilia according to the differential count (Table 1). Six of our patients had hypertension, and 5 were taking antihypertensive medications. All patients in our case series are smokers. However, they are in structured environments where they are allowed a maximum of only 6 cigarettes/day. In the 2 cases in which we were able to track the WBC counts from the beginning of clozapine treatment, the leukocytosis was noted first after 1 to 3 months of clozapine treatment. No leukocytosis was noted in these 2 patients prior to clozapine treatment, even though they were smokers, or after clozapine was discontinued. Mr. G was followed with blood counts before, during, and after treatment with clozapine. The leukocytosis was noted only during clozapine treatment, which suggests a possible association. Mr. A has been noted to have leukocytosis for more than 5 years. None of our patients had any clinical consequences associated with the leukocytosis.

The limitations of this study include the small sample size, retrospective design, smoking status of the patients, and lack of a control group.

Conclusion

Chronic leukocytosis, even though infrequent, appears to be a potential side effect of clozapine, and it is generally benign. Long-term analysis of the clozapine monitoring system data will be of help in further investigating this issue.

This study was not supported by any external funding.

Dr. Madhusoodanan is a consultant for Bristol-Myers Squibb and AstraZeneca; has received grant/research support from AstraZeneca, Janssen, and Eli Lilly; and serves on the speakers/advisory boards for Bristol-Myers Squibb and AstraZeneca. Dr. Brenner has received grant/research support from Janssen, Eli Lilly, AstraZeneca, Pfizer, and Bristol-Myers Squibb and serves on the speakers/advisory boards for Bristol-Myers Squibb, and has received honoraria from and serves on the speakers/advisory board for AstraZeneca. Drs. Cuni, Palekar, and Amambekoya report no financial affiliation or other relationship relevant to the subject of this letter.

References


LETTERS TO THE EDITOR
Occurrence of Reversible Bilateral Scotoma 1 Hour After Single-Pulse Transcranial Magnetic Stimulation: A Case Report

Sir: Transcranial magnetic stimulation (TMS) is a non-invasive method for stimulating predefined areas of the cortex. It not only is used as a neurologic technique to measure connectivity and excitability of the cortex by magnetic stimulation, but also has clear effects if added to the standard treatment of psychiatric diseases.1,2 The activation of neural tissue by TMS is not limited to the stimulated cortical area but can also spread to connected intralateral and contralateral structures.3 This activation of neuronal networks can be measured by brain imaging, especially with near-infrared spectroscopy (NIRS).4,5 Adverse effects of TMS are, especially when used in the treatment of schizophrenic patients: an international multicenter trial.6,7

Mr. A, a 30-year-old man, participated in our as-yet unpublished study combining TMS and multichannel near-infrared spectroscopy (NIRS) as a healthy participant in April 2006. He had no history of seizures or migraine. He consumed no medications, excessive caffeine, or nicotine for at least 1 week prior to TMS.

For the TMS-NIRS study, we used a Medtronic MagPro X100 TMS apparatus with a figure-of-eight coil (diameter: 70 mm, pulses: biphasic, current: posterior-anterior; Medtronic, Duesseldorf, Germany). The stimulation consisted of 3 runs with 40 stimuli each. First, the subject received sham stimulation with no magnetic field generation; then, resting motor threshold of the right abductor pollicis brevis muscle was defined.8 Afterward, we stimulated at 110% and 130% resting motor threshold over the left motor cortex. The 52-channel NIRS probe set was placed over the right motor cortex to measure changes of oxyhemoglobin and deoxyhemoglobin concentrations contralateral to stimulation site.

One hour after TMS, the participant developed a bilateral centrally localized flicker scotoma he had never experienced before. This visual phenomenon was scintillating and emerged gradually. Neither zigzag lines nor an aura around the scotoma were described. During its course, the scotoma spread to the right superior quadrant of the field of vision. Maximum of symptoms was reached 1 hour after their beginning. The symptoms abated completely after 4 hours. We sought to determine what caused the scotoma. Symptom arising from NIRS itself or by an interaction with TMS can be excluded because NIRS uses innocuous near-infrared light, which does not cause effects in neuronal tissue or interactions with electrical or magnetic fields.10 To determine if this reversible scotoma was associated with some neurologic pathology, we conducted clinical electroencephalography (EEG) and structural magnetic resonance imaging (MRI). Additionally, we classified the symptoms using the Visual Aura Rating Scale (VARS),11 a diagnostic tool for migraine with aura that consists of 5 visual symptom characteristics: duration of 5 to 60 minutes (3 points), gradual development > 5 minutes (2 points), scotoma (2 points), zigzag lines (2 points), and unilateral (1 point). A score of more than 5 points in the VARS is an indication of a migraine with aura. However, no abnormalities were found in any of these examinations.

Schulze-Bonhage12 described the differential diagnosis of visual aura in migraine and epilepsy. Visual phenomena like unilateral, temporary scotoma can emerge in both migraine and epilepsy.13 Given the existing EEG, MRI, and VARS data for Mr. A together with his exact report of the symptoms, the likelihood of a migraine-like or seizure-like background is very low.

It is known that single-pulse TMS can provoke headache during or after stimulation. Up to now, the occurrence of a flicker scotoma has not been described. An explanation for this phenomenon could be that the area of the hand motor cortex is some individuals located near the frontal eye field,14 which promotes the function of eye movement15 and projects to cortical and subcortical regions involved in visual processing.16 Because of these projections, TMS over the frontal eye field could affect visual processing mechanisms in distant cortical areas.17 We assume that we unwittingly stimulated parts of the frontal eye field, which caused the described scotoma via the visual cortex.

Even though it is still unclear if the origin of the flicker scotoma resulted from TMS, this adverse effect should be kept in mind for future studies.

Supported by grant KFO 125/1-1 from the Deutsche Forschungsgemeinschaft (German Research Community). The authors report no financial or other affiliation relevant to the subject of this letter.
REFERENCES


Kathrin C. Zierhut, M.Sc.
Melany M. Richter, M.A.
Laboratory of Psychophysiology and Functional Imaging
Department of Psychiatry and Psychotherapy
Tobias J. Renner, M.D.
Department of Child and Adolescent Psychiatry and Psychotherapy
Andreas J. Fallgatter
Laboratory of Psychophysiology and Functional Imaging
Department of Psychiatry and Psychotherapy
University of Wuerzburg
Wuerzburg, Germany

Correction

In the letter to the editor “Methadone Hydrochloride to Prevent Impulsive Behavior in Mental Retardation: A Case Report” by Abdullah M. Hasan, M.D., et al. (December 2006 issue, pp. 2032–2033), the order of authorship should have been Abdullah M. Hasan, M.D.; Michael B. Bernstein, B.S.; Geralynn Marchesi, N.P.P.; Elizabeth Lesser, M.S.W.; Mark Russ, M.D.; Arthur Rifkin, M.D.; and Alan J. Mendelowitz, M.D. The online version of the article has been corrected.

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity was supported by an educational grant from Bristol-Myers Squibb Company.